Bradmer Pharmaceuticals Inc. (TSE:GLX – Free Report) – HC Wainwright decreased their Q1 2025 earnings per share (EPS) estimates for Bradmer Pharmaceuticals in a report released on Friday, November 8th. HC Wainwright analyst M. Colonnese now forecasts that the company will earn $0.47 per share for the quarter, down from their previous forecast of $0.52. HC Wainwright currently has a “Strong-Buy” rating on the stock. HC Wainwright also issued estimates for Bradmer Pharmaceuticals’ Q2 2025 earnings at $0.56 EPS, Q3 2025 earnings at $0.65 EPS, Q4 2025 earnings at $0.77 EPS and FY2025 earnings at $2.44 EPS.
Bradmer Pharmaceuticals (TSE:GLX – Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported C($0.18) EPS for the quarter, topping analysts’ consensus estimates of C($0.52) by C$0.34.
Bradmer Pharmaceuticals Price Performance
Featured Stories
- Five stocks we like better than Bradmer Pharmaceuticals
- There Are Different Types of Stock To Invest In
- Home Depot Stock: Targeting 12% in 2024 and 25% More in 2025
- Roth IRA Calculator: Calculate Your Potential Returns
- Is Tesla’s Valuation a Bubble or Backed by Real Growth?
- Options Trading – Understanding Strike Price
- Trucking Stocks Led the Pack Last Week: Can They Keep Rolling?
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
